| 13.49 -0.45 (-3.23%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.15 | 1-year : | 19.55 |
| Resists | First : | 14.68 | Second : | 16.73 |
| Pivot price | 14.97 |
|||
| Supports | First : | 11.35 | Second : | 9.45 |
| MAs | MA(5) : | 14.39 |
MA(20) : | 14.42  |
| MA(100) : | 11.09 |
MA(250) : | 9.03 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 24 |
D(3) : | 41.4 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 16.73 | Low : | 5.67 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CGEM ] has closed above bottom band by 5.2%. Bollinger Bands are 0.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.37 - 14.51 | 14.51 - 14.59 |
| Low: | 12.84 - 13.01 | 13.01 - 13.12 |
| Close: | 13.29 - 13.57 | 13.57 - 13.74 |
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Thu, 12 Mar 2026
CGEM Earnings History & Surprises | EPS & Revenue Results | CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) - ChartMill
Wed, 11 Mar 2026
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Wed, 11 Mar 2026
Cullinan Therapeutics (CGEM): Wedbush Raises Price Target to $36 - GuruFocus
Tue, 10 Mar 2026
Cullinan Therapeutics: Q4 Earnings Insights - Cullinan Therapeutics (NASDAQ:CGEM) - Benzinga
Tue, 10 Mar 2026
Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings - AlphaStreet
Tue, 10 Mar 2026
Cullinan Therapeutics 10-K — $0 Revenue, Net Loss $219.9M - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 59 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 108.4 (%) |
| Shares Short | 8,020 (K) |
| Shares Short P.Month | 8,420 (K) |
| EPS | -3.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.63 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.6 % |
| Return on Equity (ttm) | -40.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -174 (M) |
| Levered Free Cash Flow | -99 (M) |
| PE Ratio | -4.07 |
| PEG Ratio | 0 |
| Price to Book value | 1.76 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|